๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Treatment of hepatocellular carcinoma utilizing lymphokine-activated killer cells and interleukin-2

โœ Scribed by Takafumi Ichida; Kiyohiro Higuchi; Kenji Arakawa; Hironobu Ohta; Kazuko Sugiyama; Miki Miyagiwa; Akihiro Nohzawa; Takashi Satoh; Hiroshi Sasaki; Fumihiro Ichida

Book ID
104862001
Publisher
Springer
Year
1989
Tongue
English
Weight
784 KB
Volume
23
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Adoptive immunotherapy with lymphokine-a
Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma
โœ Saburo Onishi; Toshiji Saibara; Masanao Fujikawa; Hiroshi Sakaeda; Yasushi Matsu ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 591 KB

Ten patients with hepatocellular carcinoma, three of whom had pulmonary metastasis, were treated with adoptive immunotherapy using autologous lymphokineactivated killer cells plus recombinant interleukin 2. Patients received 16 pg per day of recombinant interleukin 2 consecutively (for 14 to 64 days

Defective function of lymphokine-activat
Defective function of lymphokine-activated killer cells and natural killer cells in patients with hepatocellular carcinoma
โœ Toshiji Saibara; Saburo Onishi; Hiroshi Sakaeda; Yasutake Yamamoto ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 608 KB

Lymphokine-activated killer activity and natural killer activity in hepatocellular carcinoma patients were d. Maximum lymphokine-activated killer activity was induced at 3 to 6 days of incubation, and lymphokine-activated killer activity tended to increase in a manner dose dependent of recombinant i